Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trialEnriqueta Felip, Heather A. Wakelee, Nasser K. Altorki et al.|The Lancet|2021Cited by 1.5k
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L StudyHirotsugu Kenmotsu, Toshiaki Takahashi, Yasuto Yoneshima et al.|Journal of Thoracic Oncology|2022Cited by 158
IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).Heather A. Wakelee, Enriqueta Felip, Nasser K. Altorki et al.|Journal of Clinical Oncology|2021Cited by 117